{"transactions":[{"id":2541988,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC","position":2,"cik":"0000884731","reported_name":"ARIAD PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-10-15T18:40:19.000Z","date":"2021-10-12","kind":"exercise","acquired":false,"shares":1615427,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See explanation"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc.  ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1615427},"source":{"system":"sec-edgar","filing":"0001395064-21-000203","document":"wf-form4_163433760471855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000139506421000203/wf-form4_163433760471855.xml","form_type":"4"}},{"id":2541987,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC","position":2,"cik":"0000884731","reported_name":"ARIAD PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-15T18:40:19.000Z","date":"2021-10-12","kind":"exercise","acquired":true,"shares":1615427,"ownership":{"direct":false,"nature":"See explanation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc.  ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":1615427,"source":{"system":"sec-edgar","filing":"0001395064-21-000203","document":"wf-form4_163433760471855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000139506421000203/wf-form4_163433760471855.xml","form_type":"4"}}]}